Home
½ÃÀÛÆäÀÌÁö
Áö³È£º¸±â
·Î±×ÀÎ
ȸ¿ø°¡ÀÔ
±¸µ¶½Åû
Àüü±â»ç
2024-03-29 ±Ý 03:00
±â»ç°Ë»ö
Cover Story
¼øȯ±â
³»ºÐºñ
È£Èí±â
¼Òȱâ
½Å°æ°ú
Á¤½Å°Ç°
°¨¿°³»°ú
Sub Story
Interview
Drug Review
Conference Report
Late Breaking Studies
Expert Opinion
Primary Expert Opinion
The Rare Disease
ÇмúÀÚ¹®À§¿ø
RTM
»ó´Ü¿©¹é
񃯇
(Àüü 385°Ç)
Á¦¸ñº¸±â
Á¦¸ñº¸±â
Á¦¸ñ+³»¿ë
[Sub Story]
¸ðµç ´ç´¢º´ ȯÀÚ ¹Ì¼¼Ç÷°üÇÕº´Áõ ¼±º°°Ë»ç ÇÊ¿ä
ÀÓ¼¼Çü ±âÀÚ
2020-04-29 14:41
[Journal Briefing]
¾ß°£ °íÇ÷¾Ð ȯÀÚ, ÀÎÁö±â´É ÀúÇÏ ÁÖÀÇ
ÇãÈñÀ± ±âÀÚ
2020-04-29 14:20
[Expert Opinion]
´ç´¢º´¼º ½ÅÀ庴ÁõÀÇ °ü¸®: »õ·Î¿î ¾àÁ¦¸¦ Áß½ÉÀ¸·Î
THE MOST
2020-04-29 11:45
[Interview]
Ç÷´çÁ¶Àý ÀÌ¿Ü¿¡µµ¡¦¡°½ÉÀåºÎÅÍ ½ÅÀå±îÁö ÇýÅà ±â´ë¡±
ÀÓ¼¼Çü ±âÀÚ
2020-04-29 11:42
[Late Breaking Studies]
T2D ¸®¾ó¿ùµå¿¡¼ Å׳׸®±Û¸³Æ¾ ¾ÈÀü¼º¡¤È¿°ú È®ÀÎ
ÀÓ¼¼Çü ±âÀÚ
2020-04-29 11:37
¶óÀÎ
[Deep in Guideline]
°£°áÇÑ ¾Ë°í¸®µë ¼¼ºÐÈÇÑ ÁÖ»çÁ¦ Àü·« Á¦½Ã
ÀÓ¼¼Çü ±âÀÚ
2020-04-29 11:33
[Journal Briefing]
ÄÚÄÚ³Ó¿ÀÀÏ, ½ÉÇ÷°ü Áúȯ¿¡ 'µ¶' µÉ±î?
ÇãÈñÀ± ±âÀÚ
2020-03-26 15:55
[Journal Briefing]
½º¸¶Æ®Æù »ç¿ë, ÁøÅëÁ¦ ¾àÈ¿ ¶³¾î¶ß¸®³ª
ÇãÈñÀ± ±âÀÚ
2020-03-06 17:25
[Sub Story]
°üÇØ À¯µµ¡¤À¯Áö¿¡ 5-ASA ¿ì¼± ±Ç°í
ÀÓ¼¼Çü ±âÀÚ
2020-03-06 15:43
[Sub Story]
½ÉÇ÷°ü ÇýÅà Ç÷´ç°ÇÏÁ¦ Â÷º°È ±Ç°í
ÀÌ»óµ· ±âÀÚ
2020-01-30 15:37
¶óÀÎ
[Sub Story]
½ÉÇ÷°üÁúȯ ¿¹¹æ À§ÇÑ Ç÷´ç°ÇÏÁ¦ ¼±ÅÃ
ÀÌ»óµ· ±âÀÚ
2020-01-30 15:35
[Conference Report]
DPP-4¾ïÁ¦Á¦ ÀÎÁ¾º° È¿°úÂ÷ÀÌ ±× ÀÌÀ¯´Â?
ÀÓ¼¼Çü ±âÀÚ
2020-01-02 13:58
[Conference Report]
½ÉºÎÀü ÀûÀÀÁõ µµÀü Á¶¸í
ÀÓ¼¼Çü ±âÀÚ
2019-12-03 13:59
[Sub Story]
´ç´¢º´ ȯÀÚ ÁöÁúÄ¡·á Àü·«
ÀÓ¼¼Çü ±âÀÚ
2019-10-08 19:01
[Sub Story]
½ºÅ¸Æ¾ + ¿¡Á¦Æ¼¹Ìºê ¸ÞŸºÐ¼®±îÁö Á¢¼ö
ÀÌ»óµ· ±âÀÚ
2019-10-08 18:42
¶óÀÎ
[Sub Story]
ÀÌ»óÁöÁúÇ÷Áõ ¡°³ª È¥ÀÚ ¾È»ê´Ù¡±
ÀÌ»óµ· ±âÀÚ
2019-10-08 18:02
[Deep in Guideline]
REWIND¡¤CREDENCE ¿¬±¸ ¹Ý¿µ
ÀÓ¼¼Çü ±âÀÚ
2019-10-08 17:08
[Sub Story]
ºñ½ºÅ¸Æ¾°è º´¿ë·Ð ³ª¿À±â±îÁö
ÀÌ»óµ· ±âÀÚ
2019-10-08 15:55
[Cover Story]
¡®´ÙÁ¦¾à¹°¿ä¹ý¡¯ ½Ã´ë ¼ÒÀÓ ´ÙÇؾß!
ÀÌ»óµ· ±âÀÚ
2019-10-08 15:53
[Late Breaking Studies]
¿À¸Þ°¡-3 Áö¹æ»ê ½ÉÇ÷°ü ÇýÅà ±Ù°Å ÃàÀû Áß
ÀÓ¼¼Çü ±âÀÚ
2019-10-08 11:56
-
1
2
3
4
5
6
7
8
9
10
´ÙÀ½
-
¿©¹é
Sub
news
¡°ACEI ÀÓ»ó±Ù°Å ³õ°í, ȯÀÚ ¼³µæÇÏÀÚ¡±
Q. Ç÷¾Ð°ÇÏ Ãø¸é¿¡¼ ACEIÀÇ Æ¯¼ºÀº?ù...
¡°SGLT-2i Ȳ±Ý±â´Â TZD¿Í º´¿ëÀ¸·ÎºÎÅÍ¡±
Q. SGLT-2iÀÇ °è¿È¿°ú¿¡ ´ëÇÑ °ßÇØ´Â...
¡°°í°µµ ½ºÅ¸Æ¾ Á¦Á¦ È¿°ú ´ëµîÇϳª ¾ÈÀü¼º ´Ù¸¦ ¼öµµ¡±
Q. CAD ȯÀÚÀÇ ÀÌ»óÁöÁúÇ÷Áõ Ä¡·áÀü·«Àº?...
¿©¹é
¿©¹é
Back to Top